GlassScriptPhysician profile
Marc H Levy
NPI 1922051663
$19,239.42
in general payments reported to CMS, 2019-2025
32 companies · $1,408 in 2025
The $1,408 reported for 2025 was more than what 84% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,225 · 2020: $547 · 2021: $590 · 2022: $1,075 · 2023: $6,119 · 2024: $1,276 · 2025: $1,408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,092 · Food and Beverage: $3,712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,091.56 |
| Food and Beverage | $3,711.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $6,283.99 | 2019-2020 | |
| Samsara Vision | $5,198.11 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $1,685.31 | 2019 | |
| Horizon Therapeutics Plc | $942.74 | 2019-2023 | Tepezza |
| Regeneron Healthcare Solutions, INC. | $717.27 | 2019-2025 | Eylea Hd |
| Abbvie INC. | $713.19 | 2022-2025 | |
| Amgen INC. | $703.24 | 2019-2025 | Tepezza, Uplizna |
| Alexion Pharmaceuticals, INC. | $463.61 | 2021-2025 | Ultomiris, Soliris |
| Genentech USA, INC. | $355.48 | 2019-2024 | Vabysmo, Lucentis |
| Ani Pharmaceuticals, INC. | $307.97 | 2023-2025 | Purified Cortrophin Gel |
| Ucb, INC. | $217.72 | 2023-2025 | Zilbrysq |
| Biogen, INC. | $215.44 | 2020-2023 | Vumerity |
| Allergan, INC. | $204.59 | 2019-2022 | |
| Astellas Pharma US INC | $153.81 | 2025 | Izervay |
| Genzyme Corporation | $137.50 | 2019-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $135.38 | 2023-2025 | Dextenza |
| Eyepoint US, INC. | $126.78 | 2021 | |
| Apellis Pharmaceuticals, INC. | $121.85 | 2022 | |
| Argenx US, INC. | $85.92 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Merz Pharmaceuticals, LLC | $76.63 | 2021 | |
| Bausch & Lomb Americas INC. | $71.71 | 2025 | Xiidra, Miebo |
| Tarsus Pharmaceuticals, INC. | $62.21 | 2025 | Xdemvy |
| Alimera Sciences, INC. | $47.60 | 2020-2024 | Iluvien, Yutiq |
| Sun Pharmaceutical Industries INC. | $41.72 | 2024-2025 | |
| Pfizer INC. | $36.77 | 2023-2024 | |
| Coherus Oncology, INC. | $35.48 | 2023 | |
| Osmotica Pharmaceutical Corp. | $18.93 | 2019 | |
| Oyster Point Pharma, INC. | $18.82 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $17.32 | 2021 | |
| Harrow Eye, LLC | $14.75 | 2024 | Vevye |
| Shire North American Group INC | $14.00 | 2019 | |
| Smith+Nephew, INC. | $13.58 | 2024 | Grafix Pl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.